IMMUNITYBIO, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
IMMUNITYBIO, INC. (IBRX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $2.00 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2019-08-06
- IMMUNITYBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-06-30 was $2.00K.
- IMMUNITYBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-03-31 was -$36.00K.
- IMMUNITYBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2018-09-30 was $5.00K, a 61.54% decline year-over-year.
- IMMUNITYBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month |
|---|---|---|---|---|---|
| 2019-06-30 | $2.00K 10-Q · filed 2019-08-06 | -$34.00K 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | -$36.00K 10-Q · filed 2019-05-08 | ||||
| 2018-09-30 | $5.00K 10-Q · filed 2018-11-07 | $5.00K derived: sum of 2 quarters · filed 2019-08-06 | $5.00K 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 | ||||
| 2017-09-30 | $13.00K 10-Q · filed 2018-11-07 | -$13.00K 10-Q · filed 2017-11-07 | $17.00K derived: sum of 2 quarters · filed 2018-11-07 | $23.00K 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $4.00K 10-Q · filed 2018-08-06 | -$4.00K 10-Q · filed 2017-08-07 | $10.00K 10-Q · filed 2018-08-06 | -$10.00K 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $6.00K 10-Q · filed 2018-05-07 | ||||
| 2016-09-30 | $39.00K 10-Q · filed 2017-11-07 | -$61.00K derived: sum of 2 quarters · filed 2017-11-07 | $100.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | -$100.00K 10-Q · filed 2017-08-07 | -$200.00K 10-Q · filed 2017-08-07 | $200.00K 10-Q · filed 2016-08-15 | ||
| 2016-03-31 | $100.00K 10-Q · filed 2017-05-08 | ||||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $0.00 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |